Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06205628 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. 3 versions Re-verified since Jun 12, 2026, no change to tracked fieldsv11-v13
  2. Primary completion pushed from Jun 30, 2026 to Jul 31, 2026 Completion pushed from Sep 30, 2026 to Dec 31, 2026v10 Show 1 more changeShow less
    • Completion pushed from Sep 30, 2026 to Dec 31, 2026
  3. Re-verified, no change to tracked fieldsv9
  4. Primary completion date: Dec 31, 2025 to Jun 30, 2026 Study description shortened, about 48 words · Collaborators: 2 to 1v8 Show 2 more changesShow less
    • Study description shortened, about 48 words
    • Collaborators: 2 to 1

    See this version in full on ClinicalTrials.gov ↗

  5. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 120 to confirmed 28 · Site details revised at 3 of 3 sitesv7 Show 2 more changesShow less
    • Enrollment target: estimated 120 to confirmed 28
    • Site details revised at 3 of 3 sites
Show 5 earlier versionsHide 5 earlier versions
  1. Primary endpoints: 2 to 1 Interventions: ADX-850 (Drug), Angiotensin Receptor Blockers (Drug), Placebo (Drug) to ADX-850 (Drug), Placebo (Drug) · Eligibility criteria shortened, about 167 words · Secondary endpoints: 3 to 4 · 2 morev6 Show 5 more changesShow less
    • Interventions: ADX-850 (Drug), Angiotensin Receptor Blockers (Drug), Placebo (Drug) to ADX-850 (Drug), Placebo (Drug)
    • Eligibility criteria shortened, about 167 words
    • Secondary endpoints: 3 to 4
    • Study description shortened, about 32 words
    • Study arms: 4 to 2

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 2 to 3v5
  3. Enrollment target: 72 to 120 Primary endpoints revised (2) · Completion date: Jun 30, 2026 to Sep 30, 2026 · Eligibility criteria expanded, about 34 words · 4 morev4 Show 7 more changesShow less
    • Primary endpoints revised (2)
    • Completion date: Jun 30, 2026 to Sep 30, 2026
    • Eligibility criteria expanded, about 34 words
    • Secondary endpoints: 8 to 3
    • Study description shortened, about 7 words
    • Site contacts updated at 2 of 2 sites
    • Collaborators: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Apr 1, 2024 to Mar 21, 2024 · Site details revised at 2 of 2 sitesv3 Show 2 more changesShow less
    • Start date changed from estimate of Apr 1, 2024 to Mar 21, 2024
    • Site details revised at 2 of 2 sites
  5. Study title revisedv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in participants with hypertension.
Trial Details
NCT Number NCT06205628
Lead Sponsor ADARx Pharmaceuticals, Inc.
Collaborators: ADARx Australia Pty Ltd
Conditions Hypertension, Hypertension,Essential
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov